<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of &lt;i&gt;Haemophilus influenzae&lt;/i&gt; type b infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of <i>Haemophilus influenzae</i> type b infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of <i>Haemophilus influenzae</i> type b infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sylvia Yeh, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Haemophilus influenzae</em> serotype b (Hib) was once the most common cause of bacterial meningitis and a frequent cause of other invasive diseases (eg, epiglottitis, pneumonia, septic arthritis, bacteremia), particularly in early childhood. The widespread use of Hib conjugate vaccines in infancy has led to a dramatic decline in the incidence of invasive Hib disease in children. However, invasive Hib disease remains common in countries not using the vaccine. Other strains of <em>H. influenzae</em>, particularly nontypeable <em>H. influenzae</em> (NTHi), cause mucosal and respiratory infections throughout life.</p><p>Active immunization and chemoprophylaxis for prevention of Hib infections will be discussed here. The microbiology and epidemiology of <em>Haemophilus</em> infections and the clinical syndromes caused by <em>H. influenzae </em>(typeable and nontypeable) in children and adults are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8048.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of <i>Haemophilus influenzae</i>"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6080.html" rel="external">"Epiglottitis (supraglottitis): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6021.html" rel="external">"Acute otitis media in children: Epidemiology, microbiology, and complications"</a> and  <a class="medical medical_review" href="/z/d/html/6009.html" rel="external">"Acute otitis media in children: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6872.html" rel="external">"Acute otitis media in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6069.html" rel="external">"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a>.)</p><p></p><p class="headingAnchor" id="H110584275"><span class="h1">HIB CONJUGATE VACCINES</span><span class="headingEndMark"> — </span>Active immunization is the most important strategy for prevention of Hib infection. Licensed vaccines against nontype b strains and nontypeable strains of <em>H. influenzae</em> are not available [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H11830135"><span class="h2">Composition and storage</span><span class="headingEndMark"> — </span>Hib conjugate vaccines consist of the type b capsular polysaccharide (polyribosylribitol phosphate [PRP)] conjugated to a protein carrier (eg, the outer membrane protein complex of <em>Neisseria meningitidis</em> [OMP] or tetanus toxoid) [<a href="#rid1">1</a>]. Conjugation of PRP to a protein carrier is necessary to induce T cell-dependent memory, which increases immunogenicity in young children. Antibodies against PRP activate complement, are opsonophagocytic and bactericidal, and protect from lethal Hib challenge in animal models [<a href="#rid2">2-6</a>]. The OMP and tetanus toxoid protein carriers do not provide protection against <em>N. meningitidis</em> or tetanus.</p><p>Several Hib conjugate vaccines are licensed in the United States  (<a class="graphic graphic_table graphicRef64312" href="/z/d/graphic/64312.html" rel="external">table 1</a>). Hib conjugate vaccines licensed for use in the United States do not contain thimerosal [<a href="#rid7">7</a>].</p><p>A description of Hib conjugate vaccines for use in other countries is beyond the scope of this topic review. The World Health Organization maintains a database of vaccines that are <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fextranet.who.int%2Fpqvdata%2F&amp;token=3eD5e1iyq%2B9Jh%2FiizHrYyN8tca2EUW026H0U0Zd2PBQcAo6qEylo57lAgfpDhuLe&amp;TOPIC_ID=6022" target="_blank">prequalified for UNICEF and other United Nations agencies</a>.</p><p>Hib conjugate vaccines (whether ready-to-use or freeze-dried) and diluents (if applicable) should be stored at 35 to 46°F (2 to 8°C) [<a href="#rid8">8</a>]. Freeze-dried polyribosylribitol phosphate conjugated to tetanus toxoid (PRP-T) powder should be protected from light; the diluent must not be frozen.</p><p class="headingAnchor" id="H11830290"><span class="h2">Efficacy/effectiveness</span><span class="headingEndMark"> — </span>Prelicensure randomized trials of monovalent Hib conjugate vaccines demonstrated protective efficacy of ≥95 percent against invasive Hib disease after completion of the two- or three-dose primary series as recommended [<a href="#rid9">9-11</a>]. </p><p>With routine infant immunization, invasive Hib disease has been virtually eliminated from the United States  (<a class="graphic graphic_figure graphicRef94439" href="/z/d/graphic/94439.html" rel="external">figure 1</a>) and other countries that routinely immunize infants against Hib [<a href="#rid12">12-14</a>]. The public health benefit of routine Hib immunization exceeded expectations based on efficacy trials alone. The added benefit appears to be due to reduced carriage and transmission in the community, which extends protection to the unimmunized (ie, "herd immunity").</p><p>Routine Hib immunization has not affected the burden of disease caused by other serotypes and nontypeable <em>H. influenzae</em> (NTHi). NTHi are an important cause of acute otitis media, acute sinusitis, bronchitis, and community-acquired pneumonia and an increasingly frequent cause of invasive disease [<a href="#rid15">15</a>]. Development of NTHi vaccines is an active area of investigation [<a href="#rid16">16-18</a>].</p><p class="headingAnchor" id="H11830508"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Systemic reactions (eg, fever, irritability) are infrequent after Hib immunization [<a href="#rid19">19</a>]. Local reactions (eg, pain, redness, and/or swelling at the injection site) occur in approximately 25 percent of recipients. Local reactions usually are mild and resolve within 24 hours. The rate of adverse reactions with Hib-containing combination vaccines is similar to that when the component vaccines are administered separately [<a href="#rid20">20-22</a>].</p><p>In the United States, adverse events after vaccine administration should be reported to <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Findex.html&amp;token=8m3rK0tzv73hmwLVujPJP%2FVrZTr5LmKIlDf%2BMKp07YKCkZawMmw76Mlq0N%2Fh3R%2BM&amp;TOPIC_ID=6022" target="_blank">the Vaccine Adverse Event Reporting System (VAERS)</a>.</p><p class="headingAnchor" id="H2"><span class="h1">ROUTINE CHILDHOOD IMMUNIZATION IN THE UNITED STATES</span></p><p class="headingAnchor" id="H11836525"><span class="h2">Routine schedule</span><span class="headingEndMark"> — </span>Hib conjugate vaccine is recommended for all infants in the United States [<a href="#rid1">1,23</a>]. The routine schedule consists of a two- or three-dose primary series (at age two and four months or two, four, and six months, depending upon the vaccine formulation) and a booster dose at 12 through 15 months of age  (<a class="graphic graphic_table graphicRef77170" href="/z/d/graphic/77170.html" rel="external">table 2</a>) [<a href="#rid1">1,23</a>]. Hib conjugate vaccines can be administered at the same visit as other routine childhood immunizations  (<a class="graphic graphic_figure graphicRef82617" href="/z/d/graphic/82617.html" rel="external">figure 2A</a>) [<a href="#rid24">24</a>].</p><p>The minimum age for the first dose is six weeks; doses administered before six weeks should not be counted as valid. The recommended interval between doses in the primary series is eight weeks; however, doses separated by at least four weeks may be counted as valid [<a href="#rid1">1</a>]. The minimum age for the final dose is 12 months, and the minimum interval between the booster dose and the previous (second or third dose in the primary series) is eight weeks.</p><p>Protective levels of antibodies are achieved after two or three doses of conjugate Hib vaccines in young infants [<a href="#rid9">9,25-29</a>]. The booster dose is needed at 12 to 15 months to maximize long-term protection because of waning immunity and/or incomplete maturation of antibody by memory B cells [<a href="#rid30">30-33</a>]. Lack of a dose after 12 months of age has been associated with outbreaks of invasive Hib disease [<a href="#rid33">33-35</a>].</p><p>A 2013 systematic review of 21 randomized trials from 15 countries comparing different Hib vaccine schedules (eg, three primary doses with no booster, three primary doses with a booster, two primary doses with a booster) found little difference between schedules with respect to development of seroprotection [<a href="#rid34">34</a>]. However, children who received a booster dose were more likely to be seropositive than children of the same age who did not receive a booster dose. A separate 2013 systematic review of 30 observational studies of Hib vaccine effectiveness from 17 countries also found no particular schedule to be superior and some evidence to suggest that a booster dose provides additional protection [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H11835234"><span class="h2">Choice of vaccine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary series</strong> – Most children can receive any of the licensed vaccines  (<a class="graphic graphic_table graphicRef64312" href="/z/d/graphic/64312.html" rel="external">table 1</a>) for the primary series  (<a class="graphic graphic_table graphicRef77170" href="/z/d/graphic/77170.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">It is ideal to use the same Hib conjugate vaccine to complete the primary series. However, if it is unknown which vaccine was previously administered, or if the same vaccine is not available, the vaccines can be interchanged [<a href="#rid23">23</a>]. If two different preparations are used, a three-dose primary series is required.</p><p></p><p class="bulletIndent1">Polyribosylribitol phosphate conjugated to outer membrane protein complex of <em>N. meningitidis </em>(PRP-OMP) is preferred for American Indian/Alaska Native infants, who are at increased risk for invasive Hib disease compared with non-American Indian/Alaska Native infants [<a href="#rid1">1,23,36-38</a>]. PRP-OMP induces high antibody responses after the first dose (usually given at age two months) [<a href="#rid25">25-28,39,40</a>]. After the second dose (usually given at age four months), more than 94 percent of infants mount an adequate antibody response [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Booster dose </strong>– Any of the Hib conjugate vaccines except the combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate (Vaxelis) may be used for the booster dose  (<a class="graphic graphic_table graphicRef77170" href="/z/d/graphic/77170.html" rel="external">table 2</a>); the vaccine need not be the same as the one used for the primary series [<a href="#rid1">1,41</a>].</p><p></p><p class="headingAnchor" id="H87055353"><span class="h2">Catch-up schedule</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children &lt;5 years</strong> – The catch-up schedule for Hib conjugate vaccine in children younger than five years (whether or not they are immune compromised) depends upon the age at which the series is initiated and the number of doses previously received  (<a class="graphic graphic_table graphicRef94432" href="/z/d/graphic/94432.html" rel="external">table 3</a>) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1">The Centers for Disease Control and Prevention has developed "job aids" to provide guidance for catch-up of Hib vaccine in children &lt;5 years:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Fhib-actHib.pdf&amp;token=OB1%2FtTh%2Fb3Dl8verH6gfaCtENVJJgiToUBCZTdAjOoPIbQfvgddoKt7x%2BWD2BpqybLlAJeISBqHRd%2BvZOdgkR3XzNjQjikJ39dDw2R5bseY%3D&amp;TOPIC_ID=6022" target="_blank">Previous immunization with ActHiB, Pentacel, Menhibrix (discontinued in 2016), or unknown Hib vaccine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Fhib-pedvax.pdf&amp;token=N%2BvlL8QThFnePHKsoQZRmAZ7%2B55YAU2KEyW88UJFW7wOC8ZT1aBrehqifvIkGKGB%2FDPb1V41D5JUaAQLgQmZuNOWJW0%2Bcb5dqdWVVyzrbLU%3D&amp;TOPIC_ID=6022" target="_blank">Previous immunization with PedVaxHIB or Comvax (discontinued in 2014)</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune-competent children ≥5 years</strong> – Catch-up Hib vaccination is not indicated for immune-competent children ≥5 years of age. Natural immunity increases with age [<a href="#rid43">43-46</a>]. In the prevaccine era, invasive Hib disease occurred primarily in children younger than five years. (See  <a class="medical medical_review" href="/z/d/html/8048.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of <i>Haemophilus influenzae</i>", section on 'Hib invasive disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children ≥5 years at increased risk of invasive Hib disease</strong> – Recommendations for Hib immunization for persons ≥5 years of age who are at increased risk of invasive Hib disease are provided below. (See <a class="local">'High risk of invasive Hib disease'</a> below.)</p><p></p><p class="headingAnchor" id="H87055781"><span class="h2">Immunization in special circumstances</span></p><p class="headingAnchor" id="H87055787"><span class="h3">High risk of invasive Hib disease</span><span class="headingEndMark"> — </span>The risk of invasive Hib disease is increased in [<a href="#rid1">1,23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Anatomic or functional asplenia (including sickle cell disease)</p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection</p><p class="bulletIndent1"><span class="glyph">●</span>Immunoglobulin deficiency, including immunoglobulin G2 (IgG2) subclass deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Early component complement deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Recipients of hematopoietic stem cell transplant</p><p class="bulletIndent1"><span class="glyph">●</span>Recipients of chemotherapy or radiation therapy for malignant neoplasms</p><p></p><p>Recommendations for Hib conjugate immunization of children, adolescents, and adults at increased risk of invasive Hib disease vary according to age, number and timing of previous doses, and immune-compromising condition  (<a class="graphic graphic_table graphicRef94441" href="/z/d/graphic/94441.html" rel="external">table 4</a>) [<a href="#rid1">1,23,47</a>].</p><p>Recommendations for Hib conjugate immunization in specific high-risk populations are discussed in greater detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with anatomic or functional asplenia (or undergoing elective splenectomy) (see  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Vaccinations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with HIV infection (see  <a class="medical medical_review" href="/z/d/html/3706.html" rel="external">"Immunizations in persons with HIV", section on 'Haemophilus influenzae vaccine'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adults with cancer (see  <a class="medical medical_review" href="/z/d/html/3899.html" rel="external">"Immunizations in adults with cancer", section on 'Haemophilus influenzae vaccine'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematopoietic cell transplant candidates or recipients (see  <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients", section on 'Haemophilus influenzae'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Solid organ transplant candidates or recipients (see  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients", section on 'Haemophilus influenzae'</a>)</p><p></p><p class="headingAnchor" id="H9479034"><span class="h3">History of invasive Hib disease</span><span class="headingEndMark"> — </span>The need for Hib immunization in children with a history of invasive Hib disease depends upon the age at the time of invasive infection:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Before 24 months</strong> – Children who have invasive Hib disease before 24 months can remain at risk for a second episode of invasive Hib disease; natural infection at this age does not reliably result in protective antibody levels [<a href="#rid1">1,23,48</a>]. Such children should be immunized according to the age-appropriate schedule for <strong>unimmunized</strong> children (ie, as if they had never received Hib vaccine) [<a href="#rid1">1,23</a>]. Immunization should be initiated one month after the onset of invasive disease or as soon thereafter as possible. (See <a class="local">'Catch-up schedule'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>After 24 months</strong> – Children who have invasive Hib disease after 24 months of age virtually always develop a protective immune response and do not require immunization.</p><p></p><p>Children who develop invasive Hib disease despite two to three doses of Hib conjugate vaccine and those who have recurrent invasive Hib disease should undergo immunologic evaluation, particularly for IgG2 subclass deficiency [<a href="#rid23">23,49,50</a>]. (See  <a class="medical medical_review" href="/z/d/html/3906.html" rel="external">"IgG subclass deficiency", section on 'IgG2 deficiency'</a>.)</p><p class="headingAnchor" id="H9479301"><span class="h3">Preterm infants</span><span class="headingEndMark"> — </span>Medically stable preterm infants should be vaccinated against Hib according to the routine schedule based on their chronologic age. (See  <a class="medical medical_review" href="/z/d/html/5005.html" rel="external">"Care of the neonatal intensive care unit graduate", section on 'Immunizations'</a>.)</p><p class="headingAnchor" id="H11831625"><span class="h2">Contraindications and precautions</span><span class="headingEndMark"> — </span>Hib-containing vaccines are contraindicated in infants younger than six weeks and individuals with a severe allergy to any vaccine component (eg, latex if the vial stopper contains latex  (<a class="graphic graphic_table graphicRef64312" href="/z/d/graphic/64312.html" rel="external">table 1</a>)) [<a href="#rid1">1</a>]. Administration of Hib conjugate vaccine before six weeks of age may induce immune tolerance and reduce the response to subsequent doses [<a href="#rid51">51</a>].</p><p>Moderate or severe acute illness (ie, illness more severe than upper respiratory infection, otitis media, gastroenteritis) with or without fever is a precaution to administration of Hib conjugate vaccine [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H9479700"><span class="h2">Administration</span><span class="headingEndMark"> — </span>Each dose of Hib conjugate vaccine is 0.5 mL. Hib conjugate vaccine is administered intramuscularly, usually in the anterolateral thigh (for children &lt;3 years) or deltoid (for children ≥3 years)  (<a class="graphic graphic_table graphicRef60863" href="/z/d/graphic/60863.html" rel="external">table 5</a>). Hib conjugate vaccine may be administered at the same clinic visit as other routine childhood immunizations  (<a class="graphic graphic_figure graphicRef82617 graphicRef58209" href="/z/d/graphic/82617.html" rel="external">figure 2A-B</a>) [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H11831255"><span class="h1">ROUTINE IMMUNIZATION OUTSIDE THE UNITED STATES</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) recommends universal infant immunization against Hib [<a href="#rid54">54</a>]. Routine immunization schedules vary from country to country [<a href="#rid55">55</a>]. Schedules for individual countries are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Flisting.html%3Ftopic%3Dvaccine-schedule%26location%3D&amp;token=c1aMGh80n5JfqNiS4zUVhkGZJHzJhW7hYZJMwrVG0LFEFjNX7MxA62uBiY6p7F6hXgl8VfAnRnqUWG6LumPYIJJ9nBP597SAHqgFR7nC42s%3D&amp;TOPIC_ID=6022" target="_blank">WHO</a>.</p><p class="headingAnchor" id="H15"><span class="h1">POSTEXPOSURE CHEMOPROPHYLAXIS</span><span class="headingEndMark"> — </span>Chemoprophylaxis may be indicated for household (or close) contacts of a child with invasive Hib or <em>H. influenzae</em> type a disease, child care or preschool contacts, and the index patient, depending upon individual circumstances as described below [<a href="#rid23">23</a>]. Chemoprophylaxis generally is not indicated for contacts of people with invasive disease caused by nontype b strains of <em>H. influenzae</em>, nontype a strains of <em>H. influenzae</em>, or nontypeable <em>H. influenzae.</em></p><p class="headingAnchor" id="H17"><span class="h2">Indications</span><span class="headingEndMark"> — </span>We follow the indications for postexposure chemoprophylaxis provided by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fpreview%2Fmmwrhtml%2Frr6301a1.htm&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLINfNMwh6y7JRM6C2UhhD%2FR0sLH3i2hadoPSpkYhChOy8HBwpJwtN6zSgUDy4QzRJQ%3D%3D&amp;TOPIC_ID=6022" target="_blank">Centers for Disease Control and Prevention</a> (CDC) and the American Academy of Pediatrics (AAP), which are described below [<a href="#rid1">1,23</a>]. Guidance from <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fpublications%2Fhaemophilus-influenzae-type-b-hib-revised-recommendations-for-the-prevention-of-secondary-cases&amp;token=jB9aivydqyrt5HCUFWG0ncbK7SRjJ0nR2djCNxbzarQbADpGYVFM3dPdbHgx4bGS22tZn4NLZcl%2Bf7Xy0WX494y5tKGX66BlRstObrUxg6iwPp3APMhBXvz%2FdEHvWXyeEsAZlPb19%2B4z13wbAKuS0A%3D%3D&amp;TOPIC_ID=6022" target="_blank">Public Health England, Department of Health and NHS England</a> uses a slightly different definition of close contact and considers children younger than 10 years (rather than four years) to be susceptible to invasive Hib disease [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H18"><span class="h3">Household/close contact</span><span class="headingEndMark"> — </span>A household or close contact is defined as a person who resides with the index patient or who spent ≥4 hours with the index patient for at least five of the seven days before the day of hospital admission of the index case [<a href="#rid23">23</a>].</p><p>When there is a vulnerable household member, chemoprophylaxis is recommended for <strong>all</strong> household contacts (including the index case) [<a href="#rid23">23</a>]. This includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Household with at least one contact &lt;4 years of age who has not received an age-appropriate number of doses of Hib conjugate vaccine; in addition to chemoprophylaxis, the susceptible child(ren) should receive a dose of Hib conjugate vaccine and be scheduled for completion of Hib immunization if additional doses are necessary (see <a class="local">'Routine childhood immunization in the United States'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Household with a child &lt;12 months of age who has not completed the primary Hib series (see <a class="local">'Routine childhood immunization in the United States'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Household with a contact &lt;18 years who is immunocompromised, regardless of that child's Hib immunization status; chemoprophylaxis is not required for households with an immunocompromised adult [<a href="#rid1">1</a>]</p><p></p><p>For household/close contacts, chemoprophylaxis should be initiated as soon as possible [<a href="#rid57">57</a>]. Provision of chemoprophylaxis to household/close contacts soon after the index case is diagnosed with invasive Hib disease can eradicate nasopharyngeal carriage of Hib, thereby reducing the risk of developing invasive disease and interrupting transmission [<a href="#rid58">58-62</a>]. (See <a class="local">'Regimen'</a> below and  <a class="medical medical_review" href="/z/d/html/1289.html" rel="external">"Pathogenesis and pathophysiology of bacterial meningitis"</a>.)</p><p>In observational studies from the prevaccine era, secondary attack rates were higher among household contacts younger than four years, and particularly those younger than one year [<a href="#rid63">63-65</a>]. In a large prospective study, the overall risk of invasive Hib disease among household contacts of an index patient with Hib meningitis was 0.21 percent, many times greater than the age-adjusted risk in the general population [<a href="#rid64">64</a>]. The risk was 6 percent among infants younger than one year, 2.1 percent in children younger than four years, and 0 percent in persons ≥6 years.</p><p class="headingAnchor" id="H19"><span class="h3">Child care or preschool contacts</span><span class="headingEndMark"> — </span>Clinicians should follow local public health requirements regarding chemoprophylaxis of child care or preschool contacts of a child with invasive Hib disease.</p><p>Chemoprophylaxis for child care or school contacts after one case of invasive Hib disease is controversial. Epidemiologic studies have reached different conclusions regarding the risk among child care contacts compared with household contacts [<a href="#rid66">66</a>]. The risk among child care contacts appears to be increased relative to the general population but lower than in household/close contacts [<a href="#rid65">65,67,68</a>].</p><p>The AAP and CDC Advisory Committee on Immunization Practices recommend chemoprophylaxis for child care and preschool contacts (regardless of age or vaccine status) when unimmunized or incompletely immunized children attend the facility and two or more cases of Hib invasive disease have occurred among attendees within 60 days [<a href="#rid1">1,23</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Index patient</span><span class="headingEndMark"> — </span>Chemoprophylaxis is indicated to eradicate nasopharyngeal carriage of Hib from the index patient if they did not receive treatment for their infection with either <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> or <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a>, and the index patient <strong>either</strong> [<a href="#rid1">1,23,69-71</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Is &lt;2 years of age, <strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lives in a household with a child &lt;4 years of age who has not received an age-appropriate number of doses of Hib conjugate vaccine or an immunocompromised child &lt;18 years of age (see <a class="local">'Routine childhood immunization in the United States'</a> above)</p><p></p><p>Prophylaxis for the index patient if indicated as above should be initiated within two weeks of the onset of disease and may be initiated immediately at the end of their therapy for invasive disease.</p><p>Drugs other than <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> and <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> that may be used to treat Hib infections (eg, <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a>, <a class="drug drug_pediatric" data-topicid="13122" href="/z/d/drug information/13122.html" rel="external">cefaclor</a>) do not reliably eradicate Hib from the nasopharynx [<a href="#rid72">72-77</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Regimen</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">Rifampin</a> 20 mg/kg orally (maximum dose 600 mg) once per day for four days is the regimen of choice for Hib chemoprophylaxis in individuals ≥1 month [<a href="#rid23">23</a>]. The dose of rifampin for infants &lt;1 month of age has not been established; we suggest 10 mg/kg once per day for four days.</p><p>Consultation with an expert in infectious diseases is recommended for contacts in whom <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a> is contraindicated.</p><p>In placebo-controlled randomized trials and observational studies, <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a> eliminated nasopharyngeal carriage of Hib in greater proportions of household or day care contacts of patients with invasive Hib disease (≥95 percent versus &lt;30 percent) [<a href="#rid58">58-62</a>].</p><p>Drugs other than <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> and <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> that may be used to treat Hib infections, such as <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> [<a href="#rid72">72-74</a>], <a class="drug drug_pediatric" data-topicid="13122" href="/z/d/drug information/13122.html" rel="external">cefaclor</a> [<a href="#rid75">75,76</a>], and TMP-SMX [<a href="#rid77">77</a>], are not effective for chemoprophylaxis because they do not reliably eradicate Hib from the nasopharynx. We recommend not using these agents for antimicrobial prophylaxis against invasive Hib disease.</p><p class="headingAnchor" id="H30084033"><span class="h2">Monitoring contacts for illness</span><span class="headingEndMark"> — </span>In addition to receiving chemoprophylaxis, exposed unimmunized or incompletely immunized children who are household, child care, or preschool contacts of patients with invasive Hib disease must be observed for signs of illness [<a href="#rid23">23</a>]. Exposed children in whom febrile illness develops should receive prompt medical attention. This is especially true for twins in which a co-primary or secondary case may occur in up to 25 percent of twin pairs [<a href="#rid41">41</a>].</p><p>The child should be examined for a focus of infection; lumbar puncture may be warranted based upon clinical presentation and risk factors (eg, age, immune competence). (See  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Clinical features'</a>.)</p><p>Infections should be treated as indicated after appropriate cultures have been obtained. Parenteral antibiotics should be administered pending blood culture results if occult bacteremia is suspected. (See  <a class="medical medical_review" href="/z/d/html/8048.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of <i>Haemophilus influenzae</i>", section on 'Empiric treatment'</a> and  <a class="medical medical_review" href="/z/d/html/6075.html" rel="external">"Fever without a source in children 3 to 36 months of age: Evaluation and management", section on 'Bacteremia'</a>.)</p><p class="headingAnchor" id="H30083465"><span class="h1">INFECTION CONTROL</span></p><p class="headingAnchor" id="H30083485"><span class="h2">Hospitalized patients</span><span class="headingEndMark"> — </span>Hospitalized patients with known or suspected Hib infections should be in private rooms, and hospital personnel should wear a face mask when they are within 3 feet (1 meter) of the patient (ie, droplet precautions) for 24 hours after the initiation of parenteral antimicrobial therapy [<a href="#rid23">23</a>]. The doors of rooms used to house these patients may remain open. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Droplet precautions'</a>.)</p><p class="headingAnchor" id="H11831430"><span class="h1">RESOURCES</span><span class="headingEndMark"> — </span>Resources related to Hib immunization include:</p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpatient-care%2Fimmunizations%2F&amp;token=IQxLzDq4doJGUgaZgeIY01qsm8D6OPt1e2CZs7qNDD9Vki1c5XPFvhIarxbXlaH%2FgCiVnpr391CqcLRvxCctPg%3D%3D&amp;TOPIC_ID=6022" target="_blank">American Academy of Pediatrics</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Findex.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAH%2FK5ePuSCWLS93Qnaa3r9t3MsKItqgejFz9nciBX7e&amp;TOPIC_ID=6022" target="_blank">Centers for Disease Control and Prevention</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.immunize.org%2F&amp;token=bJ98wEjwYbR6KcGnbD%2BLoejSdbdtDpI4EQKn%2BtqVzWf7RcpJipfWejk%2Bgy%2BCZPR%2F&amp;TOPIC_ID=6022" target="_blank">Immunize.org</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Findex.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAH%2FK5ePuSCWLS93Qnaa3r8Ji8qA%2Bz6E%2B0j0H7ypMLb%2ByBTjcwubAm9%2F1KBaXNQ7aw%3D%3D&amp;TOPIC_ID=6022" target="_blank">Vaccine information statement for Hib</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fhealth-topics%2Fvaccines-and-immunization&amp;token=1V707%2B2dMduMng9ojLwnbAezNb%2FXVk1SzDDFKh0BsiJO4kL5aiy1NhkqFB1UEBVX%2B3%2B%2F9WHJ%2BpGZ4m5izww%2BpA%3D%3D&amp;TOPIC_ID=6022" target="_blank">World Health Organization</a></p><p></p><p class="headingAnchor" id="H3128487592"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109228.html" rel="external">"Society guideline links: Immunizations in children and adolescents"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110425.html" rel="external">"Society guideline links: Haemophilus influenzae type b vaccination"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1216.html" rel="external">"Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hib vaccine recommendations and efficacy</strong> – We recommend immunization of all infants with a <em>Haemophilus influenzae</em> type b (Hib) conjugate vaccine (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). In randomized trials, Hib conjugate vaccines prevented ≥95 percent of invasive Hib disease. (See <a class="local">'Hib conjugate vaccines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine Hib immunization in the United States</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Schedule – The routine schedule consists of a two-or three-dose primary series (at age two and four months or two, four, and six months, depending upon the vaccine formulation) and a booster dose at 12 to 15 months of age  (<a class="graphic graphic_table graphicRef77170" href="/z/d/graphic/77170.html" rel="external">table 2</a>). (See <a class="local">'Routine childhood immunization in the United States'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Choice of vaccine – Hib conjugate vaccines  (<a class="graphic graphic_table graphicRef64312" href="/z/d/graphic/64312.html" rel="external">table 1</a>) are generally interchangeable. However, we prefer polyribosylribitol phosphate conjugated to outer membrane protein complex of <em>Neisseria meningitidis </em>(PRP-OMP) for American Indian/Alaska Native infants. (See <a class="local">'Choice of vaccine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Catch-up schedule – The routine catch-up schedule for Hib conjugate vaccine depends upon the age at which the series in initiated and the number of doses previously received  (<a class="graphic graphic_table graphicRef94432" href="/z/d/graphic/94432.html" rel="external">table 3</a>). (See <a class="local">'Catch-up schedule'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine Hib immunization in other countries</strong> – Routine schedules for other countries are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Flisting.html%3Ftopic%3Dvaccine-schedule%26location%3D&amp;token=c1aMGh80n5JfqNiS4zUVhkGZJHzJhW7hYZJMwrVG0LFEFjNX7MxA62uBiY6p7F6hXgl8VfAnRnqUWG6LumPYIJJ9nBP597SAHqgFR7nC42s%3D&amp;TOPIC_ID=6022" target="_blank">World Health Organization</a>. (See <a class="local">'Routine immunization outside the United States'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunization of high-risk individuals</strong> – Recommendations for Hib immunization of children, adolescents, and adults at increased risk of invasive Hib disease vary according to age, number and timing of previous doses, and immune-compromising condition  (<a class="graphic graphic_table graphicRef94441" href="/z/d/graphic/94441.html" rel="external">table 4</a>). (See <a class="local">'High risk of invasive Hib disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccine administration</strong> – Hib vaccine is contraindicated in infants younger than six weeks and individuals with a severe allergy to any vaccine component. </p><p></p><p class="bulletIndent1">The dose of Hib conjugate vaccine is 0.5 mL. Hib conjugate vaccine is administered intramuscularly, usually in the anterolateral thigh (for children &lt;3 years) or deltoid (for children ≥3 years).</p><p></p><p class="bulletIndent1">Hib conjugate vaccine may be administered at the same clinic visit as other routine childhood immunizations  (<a class="graphic graphic_figure graphicRef82617 graphicRef58209" href="/z/d/graphic/82617.html" rel="external">figure 2A-B</a>). (See <a class="local">'Contraindications and precautions'</a> above and <a class="local">'Administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postexposure chemoprophylaxis</strong> – Postexposure chemoprophylaxis of household and close contacts reduces the risk of developing invasive disease and/or transmission. (See <a class="local">'Postexposure chemoprophylaxis'</a> above and  <a class="medical medical_review" href="/z/d/html/1289.html" rel="external">"Pathogenesis and pathophysiology of bacterial meningitis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Household contacts – We suggest chemoprophylaxis for household and close contacts of patients with invasive Hib disease who live in a household with individuals susceptible to invasive Hib disease (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We provide chemoprophylaxis to all members of households that include (see <a class="local">'Household/close contact'</a> above and <a class="local">'Regimen'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A child &lt;4 years who has not received an age-appropriate number of doses of Hib conjugate vaccine</p><p class="bulletIndent3"><span class="glyph">-</span>A child &lt;12 months who has not completed the primary series of Hib conjugate vaccine</p><p class="bulletIndent3"><span class="glyph">-</span>An immunocompromised child (&lt;18 years)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Child care or preschool contacts – Clinicians should follow local public health requirements regarding chemoprophylaxis of child care or preschool contacts of a child with invasive Hib disease. (See <a class="local">'Child care or preschool contacts'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Index patient – Chemoprophylaxis is indicated for index patients who did not receive at least one dose of <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> or <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> if <strong>either</strong> (see <a class="local">'Index patient'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>They are &lt;2 years of age, <strong>or</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>They live in a household with a child &lt;4 years of age who has not received an age-appropriate number of doses of Hib conjugate vaccine or an immunocompromised child &lt;18 years of age</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Briere EC, Rubin L, Moro PL, et al. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2014; 63:1.</a></li><li><a class="nounderline abstract_t">Tosi MF, Kaplan SL, Mason EO, et al. Generation of chemotactic activity in serum by Haemophilus influenzae type b. Infect Immun 1984; 43:593.</a></li><li><a class="nounderline abstract_t">Tarr PI, Hosea SW, Brown EJ, et al. The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation. J Immunol 1982; 128:1772.</a></li><li><a class="nounderline abstract_t">Steele NP, Munson RS Jr, Granoff DM, et al. Antibody-dependent alternative pathway killing of Haemophilus influenzae type b. Infect Immun 1984; 44:452.</a></li><li><a class="nounderline abstract_t">Newman SL, Waldo B, Johnston RB Jr. Separation of serum bactericidal and opsonizing activities for Haemophilus influenzae type b. Infect Immun 1973; 8:488.</a></li><li><a class="nounderline abstract_t">Myerowitz RL, Norden CW. Immunology of the infant rat experimental model of Haemophilus influenzae type b meningitis. Infect Immun 1977; 16:218.</a></li><li class="breakAll">US Food and Drug Administration. Thimerosal in vaccines. www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/UCM096228 (Accessed on October 12, 2015).</li><li class="breakAll">Centers for Disease Control and Prevention. Storage and handling for Hib vaccines. https://www.cdc.gov/vaccines/vpd/hib/hcp/storage-handling.html (Accessed on April 27, 2017).</li><li><a class="nounderline abstract_t">Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992; 121:355.</a></li><li><a class="nounderline abstract_t">Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991; 10:97.</a></li><li><a class="nounderline abstract_t">Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324:1767.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002; 51:234.</a></li><li><a class="nounderline abstract_t">Cowgill KD, Ndiritu M, Nyiro J, et al. Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA 2006; 296:671.</a></li><li><a class="nounderline abstract_t">Scheifele DW, Bettinger JA, Halperin SA, et al. Ongoing control of Haemophilus influenzae type B infections in Canadian children, 2004-2007. Pediatr Infect Dis J 2008; 27:755.</a></li><li><a class="nounderline abstract_t">Langereis JD, de Jonge MI. Invasive Disease Caused by Nontypeable Haemophilus influenzae. Emerg Infect Dis 2015; 21:1711.</a></li><li class="breakAll">ClinicalTrials.gov. Safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' nontypeable Haemophilus influenzae vaccine. https://clinicaltrials.gov/ct2/show/NCT01657526 (Accessed on October 12, 2015).</li><li class="breakAll">ClinicalTrials.gov. Vaccination for middle ear infection. https://clinicaltrials.gov/ct2/show/NCT00001605 (Accessed on October 12, 2015).</li><li><a class="nounderline abstract_t">Murphy TF. Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now. Clin Vaccine Immunol 2015; 22:459.</a></li><li><a class="nounderline abstract_t">Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120:184.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). FDA approval for infants of a Haemophilus influenzae type b conjugate and hepatitis B (recombinant) combined vaccine. MMWR Morb Mortal Wkly Rep 1997; 46:107.</a></li><li><a class="nounderline abstract_t">Guerra FA, Blatter MM, Greenberg DP, et al. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics 2009; 123:301.</a></li><li><a class="nounderline abstract_t">Black S, Greenberg DP. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Expert Rev Vaccines 2005; 4:793.</a></li><li class="breakAll">American Academy of Pediatrics. Haemophilus influenzae infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.345.</li><li><a class="nounderline abstract_t">Trofa AF, Klein NP, Paul IM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age. Pediatr Infect Dis J 2011; 30:e164.</a></li><li><a class="nounderline abstract_t">Granoff DM, Anderson EL, Osterholm MT, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992; 121:187.</a></li><li><a class="nounderline abstract_t">Bulkow LR, Wainwright RB, Letson GW, et al. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J 1993; 12:484.</a></li><li><a class="nounderline abstract_t">Vella PP, Staub JM, Armstrong J, et al. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB). Pediatrics 1990; 85:668.</a></li><li><a class="nounderline abstract_t">Shapiro ED, Capobianco LA, Berg AT, Zitt MQ. The immunogenicity of Hemophilus influenzae type B polysaccharide-Neisseria meningitidis group B outer membrane protein complex vaccine in infants and young children. J Infect Dis 1989; 160:1064.</a></li><li><a class="nounderline abstract_t">Yogev R, Arditi M, Chadwick EG, et al. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses. Pediatrics 1990; 85:690.</a></li><li><a class="nounderline abstract_t">Berrington JE, Cant AJ, Matthews JN, et al. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose. Pediatrics 2006; 117:e717.</a></li><li><a class="nounderline abstract_t">Lee YC, Kelly DF, Yu LM, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 2008; 46:186.</a></li><li><a class="nounderline abstract_t">Oh SY, Griffiths D, John T, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 2008; 197:1275.</a></li><li><a class="nounderline abstract_t">Perrett KP, John TM, Jin C, et al. Long-term persistence of immunity and B-cell memory following Haemophilus influenzae type B conjugate vaccination in early childhood and response to booster. Clin Infect Dis 2014; 58:949.</a></li><li><a class="nounderline abstract_t">Low N, Redmond SM, Rutjes AW, et al. Comparing Haemophilus influenzae type b conjugate vaccine schedules: a systematic review and meta-analysis of vaccine trials. Pediatr Infect Dis J 2013; 32:1245.</a></li><li><a class="nounderline abstract_t">Jackson C, Mann A, Mangtani P, Fine P. Effectiveness of Haemophilus influenzae type b vaccines administered according to various schedules: systematic review and meta-analysis of observational data. Pediatr Infect Dis J 2013; 32:1261.</a></li><li><a class="nounderline abstract_t">Galil K, Singleton R, Levine OS, et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis 1999; 179:101.</a></li><li><a class="nounderline abstract_t">Singleton R, Hammitt L, Hennessy T, et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics 2006; 118:e421.</a></li><li><a class="nounderline abstract_t">Briere EC, Jackson M, Shah SG, et al. Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009. Pediatrics 2012; 130:414.</a></li><li><a class="nounderline abstract_t">Campbell H, Byass P, Ahonkhai VI, et al. Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants. Pediatrics 1990; 86:102.</a></li><li><a class="nounderline abstract_t">Ahonkhai VI, Lukacs LJ, Jonas LC, Calandra GB. Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein. Vaccine 1991; 9 Suppl:S38.</a></li><li><a class="nounderline abstract_t">Kaplan SL, Mason EO Jr. Haemophilus influenzae type b disease in twins. J Pediatr 1983; 102:264.</a></li><li><a class="nounderline abstract_t">Wodi AP, Murthy N, McNally V, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:137.</a></li><li><a class="nounderline abstract_t">Fothergill LD, Wright J. Influenzal meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol 1933; 24:273.</a></li><li><a class="nounderline abstract_t">Johnston RB Jr, Anderson P, Rosen FS, Smith DH. Characterization of human antibody to polyribophosphate, the capsular antigen of Hemophilus influenzae, type B. Clin Immunol Immunopathol 1973; 1:234.</a></li><li><a class="nounderline abstract_t">Norden CW. Prevalence of bactericidal antibodies to Haemophilus influenzae, type b. J Infect Dis 1974; 130:489.</a></li><li><a class="nounderline abstract_t">Stull TL, Jacobs RF, Haas JE, et al. Human serum bactericidal activity against Haemophilus influenzae type b. J Gen Microbiol 1984; 130:665.</a></li><li><a class="nounderline abstract_t">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li><li><a class="nounderline abstract_t">Edmonson MB, Granoff DM, Barenkamp SJ, Chesney PJ. Outer membrane protein subtypes and investigation of recurrent Haemophilus influenzae type b disease. J Pediatr 1982; 100:202.</a></li><li><a class="nounderline abstract_t">Holmes SJ, Lucas AH, Osterholm MT, et al. Immunoglobulin deficiency and idiotype expression in children developing Haemophilus influenzae type b disease after vaccination with conjugate vaccine. The Collaborative Study Group. JAMA 1991; 266:1960.</a></li><li><a class="nounderline abstract_t">Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 2000; 31:973.</a></li><li class="breakAll">Oliver S, Moro P, Blain AE. Haemophilus influenzae. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 14th ed, Hall E, Wodi AP, Hamborsky J, et al (Eds). Public Health Foundation, Washington, DC 2021. https://www.cdc.gov/vaccines/pubs/pinkbook/hib.html (Accessed on February 21, 2022).</li><li class="breakAll">Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Contraindications and precautions. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html (Accessed on February 21, 2022).</li><li><a class="nounderline abstract_t">Gasparini R, Tregnaghi M, Keshavan P, et al. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. Pediatr Infect Dis J 2016; 35:81.</a></li><li class="breakAll">World Health Organization. Haemophilus influenzae type b (Hib). www.who.int/immunization/diseases/hib/en/ (Accessed on November 11, 2015).</li><li><a class="nounderline abstract_t">Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 2008; 8:435.</a></li><li><a class="nounderline abstract_t">Gkentzi D, Collins S, Ramsay ME, et al. Revised recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease. J Infect 2013; 67:486.</a></li><li><a class="nounderline abstract_t">Li KI, Wald ER. Use of rifampin in Haemophilus influenzae type b infections. Am J Dis Child 1986; 140:381.</a></li><li><a class="nounderline abstract_t">Band JD, Fraser DW, Ajello G. Prevention of Hemophilus influenzae type b disease. JAMA 1984; 251:2381.</a></li><li><a class="nounderline abstract_t">Glode MP, Daum RS, Halsey NA, et al. Rifampin alone and in combination with trimethoprim in chemoprophylaxis for infections due to Haemophilus influenzae type b. Rev Infect Dis 1983; 5 Suppl 3:S549.</a></li><li><a class="nounderline abstract_t">Granoff DM, Gilsdorf J, Gessert C, Basden M. Haemophilus influenzae type B disease in a day care center: eradication of carrier state by rifampin. Pediatrics 1979; 63:397.</a></li><li><a class="nounderline abstract_t">Glode MP, Daum RS, Boies EG, et al. Effect of rifampin chemoprophylaxis on carriage eradication and new acquisition of Haemophilus influenzae type b in contacts. Pediatrics 1985; 76:537.</a></li><li><a class="nounderline abstract_t">Shapiro ED, Wald ER. Efficacy of rifampin in eliminating pharyngeal carriage of Haemophilus influenzae type b. Pediatrics 1980; 66:5.</a></li><li><a class="nounderline abstract_t">Glode MP, Daum RS, Goldmann DA, et al. Haemophilus influenzae type B meningitis: a contagious disease of children. Br Med J 1980; 280:899.</a></li><li><a class="nounderline abstract_t">Ward JI, Fraser DW, Baraff LJ, Plikaytis BD. Haemophilus influenzae meningitis. A national study of secondary spread in household contacts. N Engl J Med 1979; 301:122.</a></li><li><a class="nounderline abstract_t">Granoff DM, Basden M. Haemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease. J Infect Dis 1980; 141:40.</a></li><li><a class="nounderline abstract_t">Daum RS, Granoff DM, Gilsdorf J, et al. Haemophilus influenzae type b infections in day care attendees: implications for management. Rev Infect Dis 1986; 8:558.</a></li><li><a class="nounderline abstract_t">Ladhani S, Neely F, Heath PT, et al. Recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease. J Infect 2009; 58:3.</a></li><li><a class="nounderline abstract_t">Band JD, Fraser DW, Hightower AW, Broome CV. Prophylaxis of Hemophilus influenzae type b disease. JAMA 1984; 252:3249.</a></li><li><a class="nounderline abstract_t">Ogle JW, Rabalais GP, Glode MP. Duration of pharyngeal carriage of Haemophilus influenzae type b in children hospitalized with systemic infections. Pediatr Infect Dis 1986; 5:509.</a></li><li><a class="nounderline abstract_t">Murphy TV, Del Rio MA, Chrane D. Persistent pharyngeal colonization during therapy in patients with meningitis caused by Haemophilus influenzae type b. J Infect Dis 1985; 152:849.</a></li><li><a class="nounderline abstract_t">Goldwater PN. Effect of cefotaxime or ceftriaxone treatment on nasopharyngeal Haemophilus influenzae type b colonization in children. Antimicrob Agents Chemother 1995; 39:2150.</a></li><li><a class="nounderline abstract_t">Gessert C, Granoff DM, Gilsdorf J. Comparison of rifampin and ampicillin in day care center contacts of Haemophilus influenzae type b disease. Pediatrics 1980; 66:1.</a></li><li><a class="nounderline abstract_t">Mason EO Jr, Kaplan SL, Lamberth LB, et al. Serotype and ampicillin susceptibility of Haemophilus influenzae causing systemic infections in children: 3 years of experience. J Clin Microbiol 1982; 15:543.</a></li><li><a class="nounderline abstract_t">Ginsburg CM, McCracken GH Jr, Rae S, Parke JC Jr. Haemophilus influenzae type b disease. Incidence in a day-care center. JAMA 1977; 238:604.</a></li><li><a class="nounderline abstract_t">Horner DB, McCracken GH Jr, Ginsburg CM, Zweighaft TC. A comparison of three antibiotic regimens for eradication of Haemophilus influenzae type b from the pharynx of infants and children. Pediatrics 1980; 66:136.</a></li><li><a class="nounderline abstract_t">Yogev R, Melick C, Kabat K. Nasopharyngeal carriage of Haemophilus influenzae type b: attempted eradication by cefaclor or rifampin. Pediatrics 1981; 67:430.</a></li><li><a class="nounderline abstract_t">Yogev R, Lander HB, Davis AT. Effect of TMP-SMX on nasopharyngeal carriage of ampicillin-sensitive and ampicillin-resistant hemophilus influenzae type B. J Pediatr 1978; 93:394.</a></li></ol></div><div id="topicVersionRevision">Topic 6022 Version 60.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24572654" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6607218" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Generation of chemotactic activity in serum by Haemophilus influenzae type b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6977569" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6609128" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antibody-dependent alternative pathway killing of Haemophilus influenzae type b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4542337" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Separation of serum bactericidal and opsonizing activities for Haemophilus influenzae type b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/301506" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Immunology of the infant rat experimental model of Haemophilus influenzae type b meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/301506" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Immunology of the infant rat experimental model of Haemophilus influenzae type b meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/301506" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Immunology of the infant rat experimental model of Haemophilus influenzae type b meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1517908" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2062621" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1903846" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11925021" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16896110" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18594482" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ongoing control of Haemophilus influenzae type B infections in Canadian children, 2004-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26407156" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Invasive Disease Caused by Nontypeable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26407156" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Invasive Disease Caused by Nontypeable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26407156" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Invasive Disease Caused by Nontypeable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25787137" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1735812" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9045037" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : FDA approval for infants of a Haemophilus influenzae type b conjugate and hepatitis B (recombinant) combined vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117896" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16372875" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16372875" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21494175" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1640282" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345981" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2107517" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2511254" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The immunogenicity of Hemophilus influenzae type B polysaccharide-Neisseria meningitidis group B outer membrane protein complex vaccine in infants and young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2107520" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549502" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171249" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422439" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24403544" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term persistence of immunity and B-cell memory following Haemophilus influenzae type B conjugate vaccination in early childhood and response to booster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145955" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparing Haemophilus influenzae type b conjugate vaccine schedules: a systematic review and meta-analysis of vaccine trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23811746" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effectiveness of Haemophilus influenzae type b vaccines administered according to various schedules: systematic review and meta-analysis of observational data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9841828" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16882783" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869828" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2113671" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1891956" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6600499" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Haemophilus influenzae type b disease in twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36757872" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Influenzal meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4543490" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Characterization of human antibody to polyribophosphate, the capsular antigen of Hemophilus influenzae, type B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4547367" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevalence of bactericidal antibodies to Haemophilus influenzae, type b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6374030" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Human serum bactericidal activity against Haemophilus influenzae type b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6977023" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Outer membrane protein subtypes and investigation of recurrent Haemophilus influenzae type b disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1895474" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Immunoglobulin deficiency and idiotype expression in children developing Haemophilus influenzae type b disease after vaccination with conjugate vaccine. The Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11049779" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11049779" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11049779" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398743" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398743" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18582836" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Haemophilus influenzae type b conjugate vaccine use and effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23831985" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Revised recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3485373" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Use of rifampin in Haemophilus influenzae type b infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6368889" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prevention of Hemophilus influenzae type b disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6605565" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Rifampin alone and in combination with trimethoprim in chemoprophylaxis for infections due to Haemophilus influenzae type b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/312483" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Haemophilus influenzae type B disease in a day care center: eradication of carrier state by rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3900905" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effect of rifampin chemoprophylaxis on carriage eradication and new acquisition of Haemophilus influenzae type b in contacts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6967587" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Efficacy of rifampin in eliminating pharyngeal carriage of Haemophilus influenzae type b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6966956" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Haemophilus influenzae type B meningitis: a contagious disease of children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/313003" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Haemophilus influenzae meningitis. A national study of secondary spread in household contacts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6965975" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Haemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3529311" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Haemophilus influenzae type b infections in day care attendees: implications for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19152980" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6334756" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prophylaxis of Hemophilus influenzae type b disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3489927" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Duration of pharyngeal carriage of Haemophilus influenzae type b in children hospitalized with systemic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3876395" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Persistent pharyngeal colonization during therapy in patients with meningitis caused by Haemophilus influenzae type b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8540735" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of cefotaxime or ceftriaxone treatment on nasopharyngeal Haemophilus influenzae type b colonization in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6967580" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Comparison of rifampin and ampicillin in day care center contacts of Haemophilus influenzae type b disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6978349" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Serotype and ampicillin susceptibility of Haemophilus influenzae causing systemic infections in children: 3 years of experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/301947" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Haemophilus influenzae type b disease. Incidence in a day-care center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6967582" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A comparison of three antibiotic regimens for eradication of Haemophilus influenzae type b from the pharynx of infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6972517" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Nasopharyngeal carriage of Haemophilus influenzae type b: attempted eradication by cefaclor or rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/308533" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effect of TMP-SMX on nasopharyngeal carriage of ampicillin-sensitive and ampicillin-resistant hemophilus influenzae type B.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
